Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Equity ETF median (66 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 26 Oct 2021 – 20 Aug 2026, limited by Aditya Birla Sun Life Nifty Healthcare ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Aditya Birla Sun Life Nifty Healthcare ETF | Nifty 500 |
|---|---|---|
| 26 Oct 2021 | ₹100.00 | ₹100.00 |
| 22 Mar 2022 | ₹97.77 | ₹95.00 |
| 15 Aug 2022 | ₹93.85 | ₹97.68 |
| 09 Jan 2023 | ₹94.05 | ₹99.68 |
| 04 Jun 2023 | ₹97.21 | ₹102.01 |
| 29 Oct 2023 | ₹108.33 | ₹108.17 |
| 24 Mar 2024 | ₹139.44 | ₹129.00 |
| 17 Aug 2024 | ₹163.71 | ₹148.75 |
| 11 Jan 2025 | ₹169.69 | ₹140.64 |
| 06 Jun 2025 | ₹166.49 | ₹149.46 |
| 31 Oct 2025 | ₹173.89 | ₹152.97 |
| 26 Mar 2026 | ₹172.05 | ₹138.57 |
| 20 Aug 2026 | ₹195.52 | ₹151.70 |
| Metric | Aditya Birla Sun Life NAV ₹16.95 Very High risk ★★★★★ | Category median Equity ETF · 66 funds |
|---|---|---|
| +13.22% | +3.95% | |
| +20.51% | +11.55% | |
| — | +10.41% | |
| — | +11.81% | |
| +14.94% | +8.19% | |
| +18.96% | — | |
| +22.00% | +13.71% | |
| — | +14.22% | |
| — | +12.98% | |
| Risk | ||
| 14.69% | 17.16% | |
| 0.95 | 0.22 | |
| 1.38 | 0.32 | |
| -18.27% | -20.98% | |
| Nifty 500 | — | |
| +9.77% | +0.65% | |
| 0.74 | 1.00 | |
| 113.5% | 101.0% | |
| 68.8% | 97.0% | |
| 0.20% | 0.37% | |
| ₹76.55Cr | ₹91.02Cr | |
| None | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Rupesh Gurav | — | |
| 26 Oct 2021 | — | |
| 20 | — | |
| 77.6% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.